GYRE THERAPEUTICS INC COM - Stock (CBIO) Institutional Ownership

CUSIP: 14888D208

13F Institutional Holders and Ownership History from Q4 2016 to Q2 2025

Type / Class
Equity / Stock
Symbol
CBIO
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Investment Quick Answers

What is CUSIP 14888D208?
CUSIP 14888D208 identifies CBIO - GYRE THERAPEUTICS INC COM - Stock in SEC 13F datasets.

Where can I see the latest institutional holders?
Use the ownership history tables below to review the newest available institutional filing periods.

Institutional Holders of GYRE THERAPEUTICS INC COM - Stock (CBIO) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q2 0 $0 -$170 0
2025 Q1 22 $170 -$12 $7.73 1
2024 Q4 15 $182 +$182 $12.13 1
2024 Q1 0 $0 -$1,696 0
2023 Q4 66 $1,696 -$1,032,317 $25.70 1
2023 Q3 2,152,048 $1,036,147 -$45,056 $0.48 30
2023 Q2 2,270,207 $796,159 -$255,684 $0.35 28
2023 Q1 3,328,636 $684,423 -$835,975 $0.21 34
2022 Q4 4,992,588 $2,631,234 -$1,437,511 $0.53 31
2022 Q3 7,733,424 $3,895,270 -$1,607,804 $0.50 32
2022 Q2 7,902,121 $14,060,954 -$492,010 $1.78 37
2022 Q1 9,682,236 $6,386,385 -$4,241,788 $0.66 41
2021 Q4 15,047,779 $13,749,621 -$26,696,387 $0.91 49
2021 Q3 18,384,148 $75,679,091 -$7,469,679 $4.11 64
2021 Q2 20,239,213 $87,684,006 -$10,728,031 $4.33 68
2021 Q1 22,416,003 $112,982,425 +$39,424,088 $5.04 87
2020 Q4 14,368,034 $90,682,601 -$1,142,136 $6.31 79
2020 Q3 14,095,053 $60,614,190 -$221,255 $4.30 76
2020 Q2 13,930,776 $81,771,833 +$19,138,343 $5.87 79
2020 Q1 10,754,400 $46,999,275 +$11,408,286 $4.37 45
2019 Q4 7,552,923 $51,432,429 +$1,256,127 $6.81 45
2019 Q3 7,443,807 $36,545,957 -$820,041 $4.91 40
2019 Q2 7,496,676 $55,311,443 -$5,216,474 $7.37 47
2019 Q1 8,110,818 $65,772,486 +$5,313,231 $8.11 60
2018 Q4 7,439,971 $58,705,892 -$5,019,285 $7.89 63
2018 Q3 7,865,370 $84,773,193 -$4,283,725 $10.78 67
2018 Q2 8,058,576 $94,038,622 -$47,610,810 $11.67 69
2018 Q1 8,524,857 $219,938,000 +$155,050,361 $25.80 51
2017 Q4 2,575,595 $35,132,000 +$18,352,374 $13.64 26
2017 Q3 1,254,597 $6,339,000 +$539,581 $5.04 10
2017 Q2 1,179,880 $5,484,000 +$4,495,339 $4.65 16
2017 Q1 182,568 $1,721,000 +$1,721,000 $9.43 10
2016 Q4 899 $1,000 +$1,000 $1.11 1